{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T23:18:15Z","timestamp":1782256695346,"version":"3.54.5"},"reference-count":53,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":1381,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1038\/s41379-018-0173-9","type":"journal-article","created":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T03:43:36Z","timestamp":1541475816000},"page":"524-531","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Programmed death ligand-1 expression in non-small cell lung cancer in a Western Australian population and correlation with clinicopathologic features"],"prefix":"10.1016","volume":"32","author":[{"given":"Linda","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connull","family":"Leslie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0461-681X","authenticated-orcid":false,"given":"Angela","family":"Jacques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Mesbah Ardakani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benhur","family":"Amanuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Millward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/s41379-018-0173-9_bib1","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"10.1038\/s41379-018-0173-9_bib2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1471-4906(01)01888-9","article-title":"PD-1: an inhibitory immunoreceptor involved in peripheral tolerance","volume":"22","author":"Nishimura","year":"2011","journal-title":"Trends Immunol"},{"key":"10.1038\/s41379-018-0173-9_bib3","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/ni944","article-title":"BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1","volume":"4","author":"Watanabe","year":"2003","journal-title":"Nat Immunol"},{"key":"10.1038\/s41379-018-0173-9_bib4","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1038\/s41379-018-0173-9_bib5","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1038\/s41379-018-0173-9_bib6","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1038\/s41379-018-0173-9_bib7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1038\/s41379-018-0173-9_bib8","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1038\/s41379-018-0173-9_bib9","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1038\/s41379-018-0173-9_bib10","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicenter, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"10.1038\/s41379-018-0173-9_bib11","doi-asserted-by":"crossref","first-page":"14209","DOI":"10.18632\/oncotarget.3694","article-title":"The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs","volume":"6","author":"Tang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1038\/s41379-018-0173-9_bib12","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/modpathol.2015.63","article-title":"Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expression in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status","volume":"28","author":"Koh","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1038\/s41379-018-0173-9_bib13","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.cllc.2015.02.002","article-title":"Programmed Death-Ligand 1 expression predicts tyrosine kinase inhibitor response and better prognosis in a cohort of patients with epidermal growth factor receptor mutation-positive lung adenocarcinoma","volume":"16","author":"Lin","year":"2015","journal-title":"Clin Lung Cancer"},{"key":"10.1038\/s41379-018-0173-9_bib14","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2147\/OTT.S59959","article-title":"Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma","volume":"7","author":"Zhang","year":"2014","journal-title":"Oncotarget"},{"key":"10.1038\/s41379-018-0173-9_bib15","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/annonc\/mdu242","article-title":"Association of PD-L1 overexpression with activating EGFR mutations in surgically resectable non-small cell lung cancer","volume":"25","author":"Azuma","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1038\/s41379-018-0173-9_bib16","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.cllc.2012.05.006","article-title":"Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung","volume":"14","author":"Boland","year":"2013","journal-title":"Clin Lung Cancer"},{"key":"10.1038\/s41379-018-0173-9_bib17","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1097\/JTO.0000000000000687","article-title":"Expression of PD-1 and its ligands, PD-L1 and PD-L2, in smokers and never smokers with KRAS mutant lung cancer","volume":"10","author":"Calles","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1038\/s41379-018-0173-9_bib18","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1177\/030089161209800612","article-title":"Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study","volume":"98","author":"Chen","year":"2012","journal-title":"Tumori"},{"key":"10.1038\/s41379-018-0173-9_bib19","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1001-9294(13)60040-1","article-title":"Relationship between programmed death-ligand 1 and clinicopathological characteristics in non-small cell lung cancer patients","volume":"28","author":"Chen","year":"2013","journal-title":"Chin Med Sci J"},{"key":"10.1038\/s41379-018-0173-9_bib20","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.lungcan.2015.05.007","article-title":"PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma","volume":"89","author":"Cooper","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1038\/s41379-018-0173-9_bib21","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/bjc.2014.555","article-title":"PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients","volume":"112","author":"D'incecco","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1038\/s41379-018-0173-9_bib22","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.lungcan.2015.01.016","article-title":"Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers","volume":"88","author":"Kim","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1038\/s41379-018-0173-9_bib23","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1158\/1078-0432.CCR-04-0428","article-title":"B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression","volume":"10","author":"Konishi","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1038\/s41379-018-0173-9_bib24","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.18632\/oncotarget.3097","article-title":"B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer","volume":"6","author":"Mao","year":"2015","journal-title":"Oncotarget"},{"key":"10.1038\/s41379-018-0173-9_bib25","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1007\/s12032-010-9515-2","article-title":"High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation","volume":"28","author":"Mu","year":"2011","journal-title":"Med Oncol"},{"key":"10.1038\/s41379-018-0173-9_bib26","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/labinvest.2013.130","article-title":"Programmed death ligand-1 expression in non-small cell lung cancer","volume":"94","author":"Velcheti","year":"2014","journal-title":"Lab Invest"},{"key":"10.1038\/s41379-018-0173-9_bib27","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.ejca.2014.01.018","article-title":"Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes","volume":"50","author":"Yang","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1038\/s41379-018-0173-9_bib28","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1038\/modpathol.2016.149","article-title":"PD-L1 expression in basaloid squamous cell lung carcinoma: Relationship to PD-1+and CD8+tumor infiltrating T cells and outcome","volume":"29","author":"Ilie","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1038\/s41379-018-0173-9_bib29","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1159\/000458412","article-title":"Impact of PD-L1 expression in patients with surgically resected non-small-cell lung cancer","volume":"92","author":"Igawa","year":"2017","journal-title":"Oncology"},{"key":"10.1038\/s41379-018-0173-9_bib30","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/j.jtho.2016.06.006","article-title":"Clinical significance of PD-L1 protein expression in surgically resected primary lung adenocarcinoma","volume":"11","author":"Takada","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1038\/s41379-018-0173-9_bib31","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.cca.2017.02.005","article-title":"PD-L1 over-expression is associated with a poor prognosis in Asian non-small cell lung cancer patients","volume":"469","author":"Xia","year":"2017","journal-title":"Clin Chim Acta"},{"key":"10.1038\/s41379-018-0173-9_bib32","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.21037\/jtd.2017.07.117","article-title":"A systematic and genome-wide correlation meta-analysis of PD-L1 expression and targetable NSCLC driver genes","volume":"9","author":"Li","year":"2017","journal-title":"J Thorac Dis"},{"key":"10.1038\/s41379-018-0173-9_bib33","article-title":"PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci Rep"},{"key":"10.1038\/s41379-018-0173-9_bib34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.lungcan.2016.04.021","article-title":"Clinical and pathologic features of lung cancer expression programmed cell death ligand 1 (PD-L1)","volume":"98","author":"Shimoji","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1038\/s41379-018-0173-9_bib35","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/2159-8290.CD-13-0310","article-title":"Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors","volume":"3","author":"Akbay","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1038\/s41379-018-0173-9_bib36","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1097\/JTO.0000000000000500","article-title":"Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driver NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation","volume":"10","author":"Chen","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1038\/s41379-018-0173-9_bib37","doi-asserted-by":"crossref","unstructured":"Huynh T, Oyarvide VM, Uruga H, Bozkurtlar E, Gainor JF, Hata AN et al. Clinicopathologic and molecular parameters of lung adenocarcinoma (ADC) associated with programmed cell death ligand 1 (PD-L1) protein expression. J Clin Oncol. 2015;33:abstr 7555.","DOI":"10.1200\/jco.2015.33.15_suppl.7555"},{"key":"10.1038\/s41379-018-0173-9_bib38","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1158\/1078-0432.CCR-15-0016","article-title":"Induction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non-small cell lung cancer","volume":"21","author":"Ota","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1038\/s41379-018-0173-9_bib39","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/PAI.0000000000000408","article-title":"Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non\u2013small-cell lung cancer","volume":"24","author":"Roach","year":"2016","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1038\/s41379-018-0173-9_bib40","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","article-title":"The2015 World Health Organization classification of lung tumors. Impact of genetic, clinical and radiologic advances since the 2004 classification","volume":"10","author":"Travis","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1038\/s41379-018-0173-9_bib41","doi-asserted-by":"crossref","unstructured":"Paz-Ares LG, Luft A, Tafreshi A, Gumus M, Mazieres J, Hermes B et al. Phase 3 study of carboplatin-paclitaxel\/nab-paclitaxel with or without pembrolizumab for patients with metastatic squamous non-small cell lung cancer. J Clin Oncol 2018;36:abstr 105.","DOI":"10.1200\/JCO.2018.36.15_suppl.105"},{"key":"10.1038\/s41379-018-0173-9_bib42","doi-asserted-by":"crossref","unstructured":"Jotte RM, Cappuzzo F, Vynnychenko I, Stroyakovskiy D, Rodriguez-Abreu D, Hussein M et al. Impower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab+carboplatin+paclitaxel or nab-paclitaxel vs carboplatin+nab-paclitaxel as 1L therapy in advanced squamous NSCLC. J Clin Oncol 2018;36:abstr LBA9000.","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA9000"},{"key":"10.1038\/s41379-018-0173-9_bib43","doi-asserted-by":"crossref","unstructured":"Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C et al. Nivolumab plus ipilimumab in lung cancer with high tumor mutational burden. N Engl J Med. 2018;378:2093\u2013104.","DOI":"10.1056\/NEJMoa1801946"},{"key":"10.1038\/s41379-018-0173-9_bib44","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1038\/s41379-018-0173-9_bib45","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-016-0943-4","article-title":"Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma","volume":"14","author":"Song","year":"2016","journal-title":"J Transl Med"},{"key":"10.1038\/s41379-018-0173-9_bib46","doi-asserted-by":"crossref","first-page":"32113","DOI":"10.18632\/oncotarget.8528","article-title":"Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer","volume":"7","author":"Inoue","year":"2016","journal-title":"Oncotarget"},{"key":"10.1038\/s41379-018-0173-9_bib47","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.lungcan.2016.05.001","article-title":"Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status","volume":"97","author":"Cha","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1038\/s41379-018-0173-9_bib48","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.jtho.2016.12.026","article-title":"Correlation between classic driver oncogene mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 \u2265 50% expression in lung adenocarcinoma","volume":"12","author":"Rangachari","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1038\/s41379-018-0173-9_bib49","doi-asserted-by":"crossref","first-page":"e0136023","DOI":"10.1371\/journal.pone.0136023","article-title":"PD-1 and PD-L1 expression in NSCLC indicate a favorable prognosis in defined subgroups","volume":"10","author":"Schmidt","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1038\/s41379-018-0173-9_bib50","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1158\/2159-8290.CD-14-1236","article-title":"Co-occuring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities","volume":"5","author":"Skoulidis","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1038\/s41379-018-0173-9_bib51","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-16-2554","article-title":"Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma","volume":"23","author":"Dong","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1038\/s41379-018-0173-9_bib52","doi-asserted-by":"crossref","first-page":"e1131379","DOI":"10.1080\/2162402X.2015.1131379","article-title":"PD-L1 expression in non-small cell lung cancer: Correlations with genetic alteration","volume":"5","author":"Scheel","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1038\/s41379-018-0173-9_bib53","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.tranon.2016.01.003","article-title":"PD-L1 expression and survival among patients with advanced non-small cell lung cancer treated with chemotherapy","volume":"9","author":"Sorensen","year":"2016","journal-title":"Transl Oncol"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41379-018-0173-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41379-018-0173-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222014612?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222014612?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41379-018-0173-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:49:28Z","timestamp":1760230168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222014612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0893395222014612"],"URL":"https:\/\/doi.org\/10.1038\/s41379-018-0173-9","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Programmed death ligand-1 expression in non-small cell lung cancer in a Western Australian population and correlation with clinicopathologic features","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/s41379-018-0173-9","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}